Brokers Issue Forecasts for CVE:QNT Q1 Earnings

Quantum Biopharma Ltd. (CVE:QNTFree Report) – Research analysts at Singular Research issued their Q1 2026 earnings estimates for shares of Quantum Biopharma in a note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan anticipates that the company will earn ($0.10) per share for the quarter. Singular Research currently has a “Moderate Buy” rating on the stock. Singular Research also issued estimates for Quantum Biopharma’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.48) EPS and Q4 2026 earnings at ($0.73) EPS.

Quantum Biopharma Stock Performance

Insider Activity

In other news, Senior Officer Nathan Patrick Coyle sold 3,000 shares of Quantum Biopharma stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of C$20.16, for a total value of C$60,480.00.

See Also

Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.